• Total Revenue: $20.2 million, a 1% increase compared to the same period in the prior year.
• Surgical Glaucoma Revenue: $18.6 million, up 1% year-over-year, with a sequential decline of 8% from Q2 2024.
• Dry Eye Revenue: $1.5 million, down 4% compared to Q3 2023.
• Gross Margin: 84%, down from 87% in the prior year period.
• Total Operating Expenses: $28.1 million, a decrease of 8% from $30.7 million in Q3 2023.
• Adjusted Operating Expenses: $23.8 million, a decrease of 11% from $26.8 million in the prior year period.
• Net Loss: $11.1 million or $0.22 per share, compared to a net loss of $13 million or $0.27 per share in Q3 2023.
• Cash and Cash Equivalents: $118.6 million at the end of the quarter.
• Debt: $35 million, excluding debt discounts and amortized debt issuance costs.
• Cash Generated: $0.4 million in the quarter, a significant improvement from $10 million cash used in Q3 2023.
• Full Year 2024 Revenue Guidance: Maintained at approximately $81 million to $83 million.
• Full Year 2024 Adjusted Operating Expenses Guidance: Revised to approximately $104 million to $106 million.

• Warning! GuruFocus has detected 4 Warning Signs with SGHT.

Release Date: November 07, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Sight Sciences Inc (NASDAQ:SGHT) reaffirmed its revenue guidance for the full year 2024, indicating confidence in its financial outlook.
• The company has developed two market-evaluated interventional technologies, OMNI and TearCare, which have been used in over 200,000 glaucoma and 60,000 dry eye procedures, respectively.
• OMNI's differentiated clinical profile is supported by high-quality long-term peer-reviewed data, which is expected to continue supporting market access.
• The company has made key organizational changes to enhance commercial execution and territory performance, which are already showing positive impacts.
• Sight Sciences Inc (NASDAQ:SGHT) ended the quarter with $118.6 million in cash and cash equivalents, reflecting financial stability and operational discipline.

Negative Points

• Revenue growth was only 1% compared to the same period in the prior year, falling short of expectations due to underperformance in surgical glaucoma revenue.
• The final 2025 Medicare payment rule did not assign device-intensive status to procedures performed with OMNI technology, which was a disappointment for the company.
• The company experienced a slower than expected recovery from the LCD's, impacting surgical glaucoma revenue and utilization.
• There was elevated trialing of lower-priced devices during the LCD process, which affected competitive positioning.
• Dry eye revenue for the third quarter was down 4% compared to the third quarter of 2023, and the company expects a significant negative impact on cash pay procedure volumes in the fourth quarter due to a price increase.

Q & A Highlights

Q: Can you provide more color on the expected sequential step-up in surgical glaucoma utilization in Q4, given the headwinds around the LCD? A: Alison Bauerlein, CFO, explained that historically, Q4 utilization is higher than Q3 due to seasonality. Improvements have been seen early in the quarter, and a targeted plan is being executed. Dry eye sales are ahead of expectations, which offsets some glaucoma shortfalls. Matt Link, CCO, added that the finalized LCD provides market certainty, allowing for deliberate re-engagement with accounts and providers.

Q: Could you explain the calculation for device-intensive status and why OMNI did not qualify in the final rule? A: Matt Link, CCO, stated that the specific claims data used for the calculation is not yet available. The process involves analyzing 2023 claims data, and the final determination showed OMNI fell below the 30% threshold. The company is committed to ensuring accurate billing data and will review the claims data once available to understand the requirements for achieving device-intensive status.

Q: How have the restrictions on multiple MIGS procedures impacted your business, and what are your expectations for 2025? A: Alison Bauerlein, CFO, noted that while the company doesn't have specific data on the impact of combination MIGS restrictions, they are proactively discussing plans with customers. The comprehensive nature of the OMNI procedure provides a unique value proposition. No specific 2025 guidance was provided, but the company is focused on leveraging OMNI's strengths.

Q: Can you discuss the progress and expectations for achieving cash flow break-even and free cash flow positivity? A: Alison Bauerlein, CFO, highlighted significant reductions in cash burn and improvements in working capital. While specific guidance on cash flow break-even is not provided, the company is focused on expense management and strategic investments, particularly in tier care market access and pipeline activities. The company feels sufficiently capitalized to support these initiatives.

Q: What is the current status and future outlook for the standalone glaucoma market? A: Matt Link, CCO, explained that the standalone market is in early development, requiring a paradigm shift in patient care. The company is focused on aligning with physicians to impact patient outcomes positively. Paul Badawi, CEO, added that real-world data from the Iris Registry supports OMNI's efficacy, with a publication expected in 2025 to further develop the standalone market.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.